Free Trial
NYSE:IKT

Inhibikase Therapeutics (IKT) Stock Price, News & Analysis

Inhibikase Therapeutics logo
$1.43 -0.12 (-7.74%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$1.44 +0.01 (+0.35%)
As of 08/8/2025 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Inhibikase Therapeutics Stock (NYSE:IKT)

Key Stats

Today's Range
$1.42
$1.56
50-Day Range
$1.43
$2.05
52-Week Range
$1.12
$4.20
Volume
142,885 shs
Average Volume
197,512 shs
Market Capitalization
$106.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50
Consensus Rating
Moderate Buy

Company Overview

Inhibikase Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

IKT MarketRank™: 

Inhibikase Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 644th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Inhibikase Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Inhibikase Therapeutics has received no research coverage in the past 90 days.

  • Read more about Inhibikase Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Inhibikase Therapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Inhibikase Therapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Inhibikase Therapeutics has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.13% of the outstanding shares of Inhibikase Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibikase Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inhibikase Therapeutics has recently decreased by 5.83%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Inhibikase Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Inhibikase Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.13% of the outstanding shares of Inhibikase Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibikase Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inhibikase Therapeutics has recently decreased by 5.83%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 7.30% of the stock of Inhibikase Therapeutics is held by insiders.

    • Percentage Held by Institutions

      Only 3.81% of the stock of Inhibikase Therapeutics is held by institutions.

    • Read more about Inhibikase Therapeutics' insider trading history.
    Receive IKT Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    IKT Stock News Headlines

    IKT Inhibikase Therapeutics, Inc. - Seeking Alpha
    Musk’s Project Colossus could mint millionaires
    I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
    See More Headlines

    IKT Stock Analysis - Frequently Asked Questions

    Inhibikase Therapeutics' stock was trading at $3.25 at the start of the year. Since then, IKT shares have decreased by 56.0% and is now trading at $1.43.

    Inhibikase Therapeutics, Inc. (NYSE:IKT) issued its quarterly earnings data on Monday, November, 15th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.24. The business had revenue of $0.33 million for the quarter.

    Inhibikase Therapeutics shares reverse split on Friday, June 30th 2023.The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

    Inhibikase Therapeutics (IKT) raised $15 million in an initial public offering (IPO) on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity​ (a division of Fordham Financial Management) served as the underwriter for the IPO.

    Inhibikase Therapeutics' top institutional shareholders include Geode Capital Management LLC (1.43%), Intech Investment Management LLC (0.04%) and Police & Firemen s Retirement System of New Jersey (0.02%). Insiders that own company stock include Milton H Werner and Arvind Kush.
    View institutional ownership trends
    .

    Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibikase Therapeutics investors own include Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), CrowdStrike (CRWD) and Intel (INTC).

    Company Calendar

    Last Earnings
    11/15/2021
    Today
    8/10/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NYSE
    Sector
    Medical
    Industry
    Biological products, except diagnostic
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NYSE:IKT
    CIK
    1750149
    Fax
    N/A
    Employees
    6
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $8.00
    Low Price Target
    $5.00
    Potential Upside/Downside
    +354.5%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.50
    Research Coverage
    2 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($2.67)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$19.03 million
    Net Margins
    N/A
    Pretax Margin
    -22,978.75%
    Return on Equity
    -350.63%
    Return on Assets
    -201.82%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    0.85
    Quick Ratio
    0.85

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $1.78 per share
    Price / Book
    0.80

    Miscellaneous

    Outstanding Shares
    74,342,000
    Free Float
    66,178,000
    Market Cap
    $106.31 million
    Optionable
    Not Optionable
    Beta
    0.90

    Social Links

    7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

    Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

    Get This Free Report

    This page (NYSE:IKT) was last updated on 8/11/2025 by MarketBeat.com Staff
    From Our Partners